drugset
drugset / Trial / NCT05207176

Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities

NCT05207176 ↗

Phase 1 Unknown 24 enrolled Daewoong Pharmaceutical Co. LTD.
NaSingle-groupOpen-labelTreatment

Summary

An open label, single center, parallel, single and multiple oral dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of DWP16001 in healthy Koreans, Caucasians, and Hispanics

Timeline

Start
2022-02-14
Primary completion
2022-04-08
Completion
2022-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Enavogliflozin Small molecule — Oral

Indications

No indication recorded.